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Abstract: Doripenem (DRPM) is a relatively new drug belonging to the 
carbapenem antibiotic group, and we hypothesized that the pharmacologic 
characteristics of DRPM might make it useful in the treatment of severe 
acute pancreatitis (SAP). We investigated the usefulness of continuous 
regional arterial infusion (CRAI) with DRPM and protease inhibitors for 
SAP. Two-hundred and forty-two patients with SAP were admitted to our 
hospital between November 2002 and June 2013. Of them, 53 patients were 
treated by CRAI with carbapenem antibiotics and nafamostat mesilate 
(NM), a serine protease inhibitor, via the celiac and superior mesenteric 
arteries. We retrospectively investigated the clinical outcomes between 34 
patients with DRPM and 19 patients with non-DRPM therapy (meropenem 
11, imipenem 6, and biapenem 2 patients). The median time to 
commencement of oral intake was significantly shorter in the DRPM group 
compared with the non-DRPM group (9 and 14 hospital days, respectively, 
p<0.01). The rate of walled-off necrosis in the DRPM group attended to be 
lower than that in the non-DRPM group (37.5 and 64.7 %, respectively, 
p=0.069). The present study suggests that CRAI with DRPM and NM for 
SAP could have equivalent therapeutic effects compared with CRAI with 
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other carbapenem antibiotics and NM. 
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Introduction 
Severe acute pancreatitis (SAP), although a benign disease, has a high 
mortality and is often refractory to treatment. The mortality rate of SAP is 
reportedly approximately 30% 1).  
The guidelines on practices in pancreatitis were successfully revised using 
a revision of the Atlanta international classification 2). According to this 
classification, changes were made in the definition, severity assessment and 
treatment strategy for SAP. SAP was defined when there was associated 
organ failure that was refractory to therapy for 48 hours.  
In recent treatment practices, patients are observed for 4 weeks for the 
development of walled-off necrosis (WON), a complication of infectious 
pancreatitis, which, if it occurs, is then treated by the recommended 
therapeutic approach of necrosectomy using a low invasive approach 3). 
Infectious pancreatic complications are an important prognostic factor of 
SAP, and it is said that continuous regional arterial infusion (CRAI) with 
antibiotics and protease inhibitors is effective in preventing infectious 
pancreatic complications and in reducing mortality following SAP 4-5). 
Recently, some articles describing CRAI using carbapenem antibiotics have 
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been reported 6-11). From these results, we adopted the therapy of CRAI 
with carbapenem antibiotics and protease inhibitors for SAP. 
SAP has a high mortality rate. Therefore, it is very difficult to perform a 
prospective study for SAP. 
The aim of this study was to evaluate the usefulness of CRAI with 
doripenem (DRPM) and the serine protease inhibitor nafamostat mesilate 
(NM) for SAP. DRPM is a relatively new drug belonging to the 
carbapenem antibiotic group, and we hypothesized that the pharmacologic 
characteristics of DRPM might make it useful in the treatment of SAP. We 
compared the safety and efficacy of CRAI with DRPM and NM for SAP 
versus therapy with other carbapenem antibiotics by assessing the adverse 
events and mortality of SAP following treatment with the different 
carbapenem antibiotics. 
 
Material and methods 
Two-hundred and forty-two patients with SAP were admitted to Showa 
University Hospital between November 2002 and June 2013. Fifty-three of 
them underwent treatment involving CRAI with carbapenem antibiotics 
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and NM via the celiac and superior mesenteric arteries. We retrospectively 
investigated the clinical outcomes, such as infectious complications and 
mortality, between 34 patients who received DRPM and 19 patients who 
received non-DRPM therapy (meropenem: MEPM 11, imipenem: IPM 6, 
and biapenem: BIPM 2 patients). 
In Japan, the prognostic factors and CT grading for acute pancreatitis 12), 
which was developed by the Research Committee of Intractable Diseases 
of the Pancreas, the Ministry of Health, Labour and Welfare, are utilized for 
assessment of the severity of acute pancreatitis (Table 1). 
CRAI was employed in patients with severe acute necrotizing pancreatitis, 
defined as lack of enhancement of pancreatic parenchyma on contrast 
enhanced computed tomography (CE-CT).  
The drugs administered by CRAI included NM (240 mg/day) together 
with either DRPM 1.5 g/day (0.5 g every 8 hours), MEPM 2 g/day (1 g 
every 12 hours), IPM 2 g/day (1 g every 12 hours), or BIPM 1.2 g/day (0.6 
g every 12 hours), the antibiotic being chosen at the discretion of the 
attending physician. 
Continuous variables are expressed as medians with a range. Statistical 
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analyses were performed using StatMate III software (ATMS Co., Ltd., 
Tokyo, Japan). Data were analyzed by the Mann-Whitney U-test and 
Chi-squared test, with differences of p<0.05 being considered statistically 
significant.  
This retrospective study was approved by the ethics committee of our 
hospital. 
 
Results 
 Median age of the 53 SAP patients was 49 years (range, 15-85 years; 41 
men and 12 women). Disease etiology included alcoholic pancreatitis in 34, 
gallstones in 2, idiopathic pancreatitis in 13, and other diseases in 4 cases. 
The median Japanese prognostic factors score within 48 hours after 
admission was 4 points (range, 0-8 points). CE-CT grade 2 disease was 
present in 30 cases, and grade 3 disease in 23 cases. Median acute 
physiology and chronic health evaluation (APACHE) II score was 10 points 
(range, 0-31 points), and median sequential organ failure assessment 
(SOFA) score was 2 points (range, 0-10 points). 
The median day of commencement of CRAI was hospital day 1 (range, 
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1-4 days), median duration of CRAI was 5 days (range, 3-7 days), and 
mortality rate was 9.4%.  
There were no significant differences in patient characteristics between 
DRPM and non-DRPM groups (in terms of age, sex, etiology, Japanese 
prognostic factors score, CE-CT grade, APACHE-II score, SOFA score, 
start day of CRAI, and duration of CRAI) (Table 2). No significant 
differences were observed in disappearance of abdominal pain, duration of 
administration of antibiotics, early organ dysfunction rate, late severe 
infection rate, surgery rate, duration of admission and mortality. Median 
day of commencement of oral feeding was significantly earlier in the 
DRPM group compared with the non-DRPM group (9 and 14 hospital days, 
respectively, p<0.01). The rate of WON in the DRPM group tended to be 
lower than that in the non-DRPM group (37.5% and 64.7%, respectively, 
p=0.069) (Table 3). Adverse events due to CRAI with DRPM and NM for 
SAP included increase in serum bilirubin levels in five cases (two cases of 
increase in AST, ALT), one case of subarachnoid hemorrhage (SAH) and 
one case of obstruction of the artery of the lower extremity. 
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Discussion 
When acute pancreatitis is suspected, its severity needs to be determined 
so that appropriate treatment can be provided. In severe cases, strict 
circulatory and respiratory management are necessary. 
In our hospital, we perform CRAI in patients with severe acute necrotizing 
pancreatitis, and perform continuous hemodiafiltration (CHDF) in cases of 
SAP with organ dysfunction. Further, we provide early enteral nutrition as 
infection prophylaxis for SAP. 
In Japan, it is not considered necessary to administer antibiotics 
prophylactically to patients with mild acute pancreatitis, because of the low 
rate of infectious complications and mortality. While prophylactic 
administration of antibiotics for SAP can improve the prognosis and 
decrease the incidence of infectious pancreatic complications, it is 
necessary to consider the anti-bacterial spectrum, pancreatic tissue 
concentration and dosing period of antibiotics for SAP.  
However, the 2006 American pancreatic guidelines do not recommend 
prophylactic antibiotic therapy in these patients 13). 
Buchler et al. 14) examined pancreatic tissue concentrations of each 
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antibiotic. They showed that imipenem (carbapenem antibiotics), ofloxacin 
and ciprofloxacin (new quinolone) had high pancreatic tissue 
concentrations and extensive bactericidal activity for most bacteria. 
Therefore, we examined the usefulness of prophylactic antibiotics. There 
are some reports of the prophylactic use of antibiotics for severe 
pancreatitis 15-26). The efficacy of prophylactic use of antibiotics for acute 
pancreatitis was first reported after the introduction of carbapenem 
antibiotics in the 1990s, including the report of use of imipenem by 
Pederzoli et al 15). Recently, carbapenem antibiotics for SAP have been 
recommended in Japan 7-10). 
There are some placebo-controlled double blind studies evaluating 
transvenous prophylactic antibiotic therapy 21-22). These studies suggested 
that prophylactic antibiotic therapy for SAP does not necessarily lead to a 
decrease in infectious pancreatic complications and mortality rate. However, 
these studies varied in the type of antimicrobial agent, route of 
administration and start day of antibiotics. Therefore, denying early 
prophylactic antibiotic therapy based on these studies is not appropriate. 
On the other hand, a randomized controlled trial (RCT) on early 
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prophylactic antibiotic therapy for SAP showed decreasing infectious 
pancreatic complications and mortality rate with such therapy 25). Manes et 
al.22) conducted an RCT using meropenem for necrotizing pancreatitis. 
They divided patients into two groups based on the timing of 
commencement of antibiotic administration, namely, at admission and after 
CE-CT confirmation of the pancreatic necrosis area. Pancreatic infection 
occurred in 13% of patients in the former group and 31% in the latter group, 
with extrapancreatic infection being observed in 17% and 45%, 
respectively. Pancreatic and extrapancreatic infection rates in the former 
group were significantly lower than those in the latter group. Besides, the 
former group had lower surgery rates and shorter periods of admission than 
patients in the latter group. Their study, therefore, suggests that antibiotic 
therapy initiation time is an important determinant of patient outcome. 
CRAI for acute necrotizing pancreatitis was reported by Takeda et al. 4), 
and came to be recognized as appropriate therapy for SAP. The purpose of 
CRAI is to directly deliver a high concentration of the protease inhibitor 
and antibiotic at the site of inflammation and necrotic tissue by 
intra-arterial injection, to prevent local pancreatic inflammation and 
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infection. NM acts as a protease inhibitor at low concentrations and as an 
anticoagulant at high concentrations. It is estimated that the pancreatic local 
site concentrations of drugs administered by intra-arterial injection for 
CRAI reach a concentration of 9 times or more than that following 
intravenous infusion 27). Takeda et al. 4) reported that NM inhibits the 
extension of pancreatic necrosis by its anticoagulant action in the 
microcirculation, and is effective for prevention of vasospasm and vascular 
occlusion. In their study, intraperitoneal infections, infections due to 
pancreatic necrosis and mortality were significantly lower in the NM than 
the non-NM group. 
Hayashi et al. 6) reported the utility of CRAI via the celiac artery, and 
Takagi et al. 5) reported the usefulness of CRAI via the superior mesenteric 
artery.  
In studies that divided SAP into CRAI and non-CRAI groups, infectious 
pancreatic complications, surgical rate and mortality in the CRAI group 
were lower than those in the non-CRAI group 7-8). It was also reported that 
the group that received CRAI with gabexate mesilate as the protease 
inhibitor for SAP had shorter duration to disappearance of abdominal pain, 
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SIRS positive scores and hospitalization than the non-CRAI group 9). 
Ishikawa et al. 10) reported the usefulness of CRAI with NM and IPM for 
SAP. The mortality rate in the group that started CRAI within three days of 
the onset of SAP was significantly lower than in the group that started 
CRAI after three days (0% and 66.7%, respectively.) They concluded that 
the timing of CRAI initiation is extremely important, and that CRAI should 
be initiated within three days of the onset of SAP for greater efficacy. 
An RCT of CRAI for SAP was first reported by Piascik et al 11). They 
randomly divided 78 patients within 72 hours from the onset of acute 
pancreatitis to hospitalization into CRAI (39 cases) and non-CRAI groups 
(39 cases). The CRAI group was treated continuously with 240 mg/day of 
NM and 1 g/day of IPM for 5 days as an arterial infusion via one of the 
arteries perfusing the pancreas, following which IPM was given 
intravenously (0.5 g every 8 hours) for at least 9 days. The non-CRAI 
group received IPM (0.5 g every 8 hours) intravenously for 14 days. The 
CRAI group had a lower mortality rate than the non-CRAI group, showing 
that CRAI using a protease inhibitor and antibiotic for SAP is effective in 
preventing adverse events and in reducing mortality rates. 
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Recently, a pharmacokinetics-pharmacodynamics (PK-PD) theory was 
proposed 28-29). β-lactam antibiotics, such as carbapenem antibiotics, are 
drugs with time-dependent bactericidal activity. In vivo, the proliferative 
inhibitory effect and maximal bactericidal action correlate with the time for 
which the drug concentration exceeds its minimum inhibitory concentration 
(MIC) (%T>MIC).  
In this study, we chose DRPM as the antibiotic evaluated for the following 
reasons. 
(1) DRPM is highly effective against not only aerobic gram-negative and 
gram-positive bacteria, but also anaerobic bacteria. In addition, it 
suppresses the growth of antimicrobial resistant P. aeruginosa. 
(2) DRPM, MEPM and IPM exhibit potent activity, with MIC90 of 4, 16 
and 32 μg/mL, respectively. DRPM is clinically effective against P. 
aeruginosa infection.  
(3) DRPM does not show any cross resistance with MEPM and IPM 
against P. aeruginosa. 
(4) Incompatibility between DRPM and protease inhibitors is low. 
(5) DRPM is a drug with little effect on the central nervous system 30-36). 
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Also, it is said that as the number of doses of DRPM that are administered 
increases, the time above the MIC of DRPM increases, based on the 
observed changes in its plasma concentration in healthy adults in a phase I 
study 14). 
In the current study, the incidence of WON in the DRPM group tended to 
be lower than that in the non-DRPM group, indicating the clinical efficacy 
of CRAI with DRPM and NM. 
One study compared the MIC90 of DRPM, IPM and MEPM for the main 
microorganism strains affected by them. In most strains, the MIC90 level of 
DRPM was lower than that of IPM and MEPM 29).  
In our study, it is possible that synergy between DRPM and NM led to the 
decrease in the incidence of WON. 
The present study suggests that CRAI with DRPM and NM for SAP could 
provide equivalent therapeutic effects compared with CRAI with other 
carbapenem antibiotics and NM. 
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Table 1. Japanese severity scoring system for acute pancreatitis by the 
Ministry of Health, Labour and Welfare of Japan (2008 revision) 
Prognostic factors (1 point for each factor)  
1. Base excess ≤ -3 mEq/L or shock (systolic blood pressure < 80 mmHg) 
2. PaO2 ≤ 60 mmHg (room air) or respiratory failure (requiring ventilatory 
management) 
3. BUN ≥ 40 mg/dL or creatinine ≥ 2.0 mg/dL or oliguria (daily urine 
output < 400 mL even after intravenous fluid resuscitation) 
4. LDH ≥ twice the upper limit of normal 
5. Platelet count ≤ 100,000/mm3 
6. Serum Ca ≤ 7.5 mg/dL 
7. CRP ≥ 15 mg/dL 
8. Number of positive measures in SIRS criteria ≥ 3 
9. Age ≥ 70 years 
CT grade based on contrast-enhanced CT 
1. Extrapancreatic progression of inflammation 
Anterior pararenal space      0 point 
Root of mesocolon       1 point 
Beyond lower pole of kidney     2 points 
2. Hypo-enhanced lesion of the pancreas 
The pancreas is conveniently divided into three segments (head, body, and 
tail). 
Localized in each segment or only surrounding the pancreas 0 point 
Extends to 2 segments      1 point 
Occupies entire 2 segments or more     2 points 
1 + 2 = total score 
Total score of 0 or 1       grade 1 
Total score of 2       grade 2 
Total score of 3 or more      grade 3 
Assessment of severity 
If prognostic factors score is ≥ 3, or CT grade is ≥ 2, the disease is graded 
as ‘severe’. 
Measurements in SIRS criteria include body temperature > 38°C or < 
36°C, heart rate > 90 beats/min, respiratory rate > 20 breaths/min or PaCO2 
≤ 32 torr, and white blood cell counts > 12,000 cells/mm3, < 4,000 
 25 
 
cells/mm3, or > 10% immature (band) forms 
BUN, blood urea nitrogen; LDH, lactate dehydrogenase; CRP, C-reactive 
protein; SIRS, systemic inflammatory response syndrome; CT, computed 
tomography 
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Table 2. Comparison of patient characteristics between DRPM and 
non-DRPM groups 
 
DRPM 
group 
(n=34) 
Non-DRPM 
group 
(n=19) 
p value 
Median age, years (range) 51 (19-85) 48 (15-83) N.S. 
Sex: male/female 27/7 14/5 N.S. 
Etiology: 
Alcohol/Gallstones/Idiopathic/Others 
24/1/7/2 10/1/6/2 N.S. 
Median Japanese prognostic factors 
score, points (range) 
3 (0-7) 4 (1-8) N.S. 
CE-CT Grade, grade 1/2/3 0/22/12 0/8/11 N.S. 
Median APACHE-II score, points 
(range) 
11 (0-28) 9 (1-31) N.S. 
Median SOFA score, points (range) 3 (0-10) 2 (0-10) N.S. 
Median start time of CRAI, hospital 
days (range) 
1 (1-3) 1 (1-4) N.S. 
Median duration of CRAI, days 
(range) 
5 (3-5) 5 (3-7) N.S. 
N.S., not significant; DRPM, doripenem; CE-CT, contrast enhanced 
computed tomography; APACHE, acute physiology and chronic health 
evaluation; SOFA, sequential organ failure assessment; CRAI, continuous 
regional arterial infusion 
 
 
 
 
 
 
 
 
 
 
 
 
 27 
 
Table 3. Comparison of clinical outcomes between DRPM and non-DRPM 
groups 
 DRPM 
group 
(n=34) 
Non-DRPM 
group 
(n=19) 
p value 
Disappearance of abdominal 
pain, median hospital days 
(range) 
5 (2-12) 5 (3-15) N.S. 
Start day of oral intake, median 
hospital days (range) 
9 (4-35) 14 (10-93) < 0.01 
Duration of administration of 
antibiotics, median no. of days 
(range) 
12 (3-57) 13 (3-143) N.S. 
Early organ dysfunction rate, % 
(no./total.no) 
64.7 (22/34) 84.2 (16/19) N.S. 
Late severe infection rate, % 
(no./total.no) 
13.3 (4/30) 17.6 (3/17) N.S. 
Surgery rate, % (no. /total no.) 2.9 (1/34) 5.3 (1/19) N.S. 
WON rate, % (no./total.no.) 37.5 (12/32) 64.7 (11/17) N.S. 
(0.069) 
Median duration of admission, 
days (range) 
21 (3-115) 25 (3-172) N.S. 
Mortality, % (no./total.no.) 8.8 (3/34) 10.5 (2/19) N.S. 
N.S., not significant; WON, walled-off necrosis 
